Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
DHR Stock Summary
Top 10 Correlated ETFs
In the News
Danaher Corporation: A Good Contrarian Bet
Danaher Corporation is facing near-term headwinds due to COVID-19-related demand normalization and customer inventory destocking in its Biotechnology segment. However, these headwinds are temporary, and the company's medium to long-term growth story is attractive. The company has a healthy balance sheet, strong exposure to high-growth end markets like Biologics, and a history of driving shareholder value through portfolio transformation and strategic M&A.
Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Danaher focuses on innovation for steady, high-value recurring revenue, driving financial stability. Aging population, longer lifespans, and tech advances drive Danaher's sector toward significant growth. I expect a 10% revenue dip from lowered COVID-19 product sales, with recovery projected in 12 months.
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
The U.S. continues to spend more money on healthcare than any other country. Healthcare spending totaled $4.3 trillion, according to the American Medical Association.
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 at 3:00 p.m.
Last Call: 3 Growth Stocks to Buy Before New Year's Eve
In the shifting sands of the current stock market, discerning investors continue to navigate a labyrinth of uncertainties. Yet, the allure of long-term growth stocks remains undiminished.
Three value stock picks from a veteran manager with a good performance record
For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech-driven market decline for 2022 might have made some investors think again about different investment styles for the long term.
A New Bull Market Is Coming! 3 Stocks Set to Soar 65% to 132% Higher
Regardless of whether you're a Wall Street veteran or new to investing, the past four years have been a roller coaster ride. A global pandemic brought a 14-year-long bull market to a screeching halt.
Make Me a Millionaire: 3 Top Growth Stocks to Buy Now
The stock market is on the downswing. Many traders are dumping their holdings as inflation, interest rates, and geopolitical crises weigh heavily on sentiment.
Danaher's (DHR) Q3 Earnings & Revenues Beat, Decline Y/Y
While Danaher (DHR) surpasses Q3 earnings and revenue estimates, the company's performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Life Sciences segment.
Danaher 3Q earnings beat but shares fall on disappointing outlook
Danaher (NYSE:DHR)'s third quarter earnings topped Wall Street estimates on the top and bottom lines but its weak guidance saw investors retreat from the stock. The company - which designs, manufactures and markets products and services across a range of industries including medical and industrial – reported a 10.5% year-over-year drop in revenue to $6.9 billion.
DHR Financial details
DHR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||28.39||25.05||31.55||41.22||43.4|
|Net income per share||3.78||4.21||5.16||9||9.94|
|Operating cash flow per share||5.74||5.53||8.79||11.7||11.75|
|Free cash flow per share||4.91||4.64||7.67||9.89||10.16|
|Cash per share||1.12||27.85||8.55||3.62||8.27|
|Book value per share||40.27||42.34||56.31||63.21||69.07|
|Tangible book value per share||-13.35||-3.05||-23.97||-26.38||-13.74|
|Share holders equity per share||40.27||42.34||56.31||63.21||69.07|
|Interest debt per share||14.13||30.54||30.41||31.37||27.43|
|Price to sales ratio||3.22||5.43||6.24||7.08||5.42|
|EV to sales||3.67||5.53||6.92||7.74||5.86|
|Enterprise value over EBITDA||15.34||21.5||25.22||22.58||17.18|
|EV to operating cash flow||18.15||25.08||24.85||27.28||21.63|
|EV to free cash flow||21.23||29.88||28.47||32.28||25.02|
|Free cash flow yield||0.05||0.03||0.04||0.03||0.04|
|Debt to equity||0.35||0.72||0.53||0.49||0.39|
|Debt to assets||0.2||0.35||0.28||0.27||0.23|
|Net debt to EBITDA||1.88||0.39||2.48||1.94||1.28|
|Sales general and administrative to revenue||0||0||0||0||0|
|Research and developement to revenue||0.06||0.06||0.06||0.06||0.06|
|Intangibles to total assets||0.79||0.52||0.74||0.77||0.71|
|Capex to operating cash flow||-0.15||-0.16||-0.13||-0.15||-0.14|
|Capex to revenue||-0.03||-0.04||-0.04||-0.04||-0.04|
|Capex to depreciation||-0.45||-0.53||-0.45||-0.6||-0.52|
|Stock based compensation to revenue||0.01||0.01||0.01||0.01||0.01|
|Return on tangible assets||0.26||0.1||0.19||0.34||0.3|
|Tangible asset value||-9.35B||-2.18B||-16.93B||-18.85B||-9.96B|
|Net current asset value||-12.51B||-6.2B||-22.58B||-26.36B||-18.38B|
|Days sales outstanding||64.03||65.04||66.25||57.39||57.04|
|Days payables outstanding||71.16||69.73||76.24||81.53||66.93|
|Days of inventory on hand||79.35||74.97||85.29||87.81||90.65|
|Capex per share||-0.83||-0.89||-1.12||-1.81||-1.59|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-29 for Q3
|Revenue per share||10.52||11.48||9.83||9.71||9.3|
|Net income per share||2.16||3.06||1.99||1.5||1.53|
|Operating cash flow per share||2.76||3.49||2.67||2.61||2.26|
|Free cash flow per share||2.38||3.03||2.29||2.15||1.77|
|Cash per share||7.07||8.22||10.12||11.63||16.6|
|Book value per share||64.5||68.71||70.58||70.14||70.88|
|Tangible book value per share||-15.4||-13.67||-11.44||-9.72||-7.47|
|Share holders equity per share||64.5||68.71||70.58||70.14||70.88|
|Interest debt per share||26.48||27.08||27.28||27.05||29.93|
|Price to sales ratio||21.77||20.49||22.74||21.92||23.66|
|EV to sales||23.61||22.13||24.48||23.5||25.09|
|Enterprise value over EBITDA||70.2||82.05||73.07||115.27||83.21|
|EV to operating cash flow||90||72.88||90.1||87.32||103.12|
|EV to free cash flow||104.39||83.72||104.92||106.1||131.92|
|Free cash flow yield||0.01||0.01||0.01||0.01||0.01|
|Debt to equity||0.41||0.39||0.39||0.38||0.42|
|Debt to assets||0.24||0.23||0.23||0.23||0.25|
|Net debt to EBITDA||5.47||6.06||5.19||7.75||4.72|
|Sales general and administrative to revenue||0||0||0||0||0|
|Research and developement to revenue||0.05||0.05||0.06||0.06||0.06|
|Intangibles to total assets||0.72||0.71||0.7||0.69||0.66|
|Capex to operating cash flow||-0.14||-0.13||-0.14||-0.18||-0.22|
|Capex to revenue||-0.04||-0.04||-0.04||-0.05||-0.05|
|Capex to depreciation||-0.51||-0.58||-0.49||-0.61||-0.66|
|Stock based compensation to revenue||0.01||0.01||0.01||0.02||0.01|
|Return on tangible assets||0.07||0.09||0.06||0.04||0.04|
|Tangible asset value||-11.22B||-9.96B||-8.35B||-7.17B||-5.53B|
|Net current asset value||-19.79B||-18.38B||-17.02B||-15.72B||-14.11B|
|Days sales outstanding||51.78||52.89||54.16||52.8||55.01|
|Days payables outstanding||64.04||60.24||66.96||56.5||59.33|
|Days of inventory on hand||94.59||81.6||108.86||91.94||94.73|
|Capex per share||-0.38||-0.45||-0.38||-0.46||-0.49|
DHR Frequently Asked Questions
What is Danaher Corporation stock symbol ?
Danaher Corporation is a US stock , located in Washington of Dc and trading under the symbol DHR
Is Danaher Corporation buy or a sell ?
19 stock analysts have 19 predictions with a medium analyst target price of $320.74. The lowest prediction is $265 and the highest is $370
What is DHR stock prediction ?
With a median analyst target price of $300, 1 stock analysts have made 1 forecasts in last 90 days. $300 is the lowest and $300 is the greatest projection.
What is Danaher Corporation stock quote today ?
Danaher Corporation stock price is $222.86 today.
Is Danaher Corporation stock public?
Yes, Danaher Corporation is a publicly traded company.